Metabolic syndrome among patients receiving clozapine: a preliminary estimate
subho chakrabarti
Indian Journal of Pharmacology 2011; 43:591-595.
View PDFchevron_right
A longitudinal study of change in prevalence of metabolic syndrome and metabolic disturbances 3 months after clozapine therapy
subho chakrabarti
Journal of Mental Health and Human Behaviour 2013; 18: 9–17.
View PDFchevron_right
An Archival, Follow-Forward Exploration of the Metabolic Syndrome in Randomly Selected, Clozapine-Treated Patients
Nina Skuban
Clinical Schizophrenia & Related Psychoses, 2009
View PDFchevron_right
Prevalence and associations of the metabolic syndrome among patients prescribed clozapine
Colm McDonald
Irish Journal of Medical Science, 2008
View PDFchevron_right
Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
Philip B Ward
Schizophrenia research, 2018
View PDFchevron_right
Physical Health Monitoring for Metabolic Syndrome in Patients Prescribed Olanzapine in Oman
Mundher Al-Maqbali
View PDFchevron_right
Incidence of Metabolic Syndrome in patients treated with Clozapine in a tertiary care center in central Kerala
praveenlal kuttichira
Kerala Journal of Psychiatry
View PDFchevron_right
Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia
Scott Lamont
Archives of Psychiatric Nursing, 2009
View PDFchevron_right
EPA-1059 – Metabolic syndrome in patients with schizophrenia: polypharmacy with first generation antipsychotics vs. clozapine alone
Enes Osmanović
Psychiatria Danubina, 2015
View PDFchevron_right
Correlation between clozapine use and metabolic syndrome in schizophrenic patients
Zullies Ikawati
Pharmacy Education
View PDFchevron_right
Metabolic monitoring of second-generation antipsychotics: Evaluation of a pharmacist- and nurse-driven protocol
Jasmine Gonzalvo
Journal of the American Pharmacists Association, 2020
View PDFchevron_right
Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications
antony fernandez
Primary Care Diabetes, 2009
View PDFchevron_right
The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
Oriana Delgado
2020
View PDFchevron_right
Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India
Sahana Shetty
Asian Journal of Psychiatry, 2020
View PDFchevron_right
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment
Ric Procyshyn
Journal of psychiatry & neuroscience: JPN
View PDFchevron_right
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring
Andre de nayer
International Clinical Psychopharmacology, 2006
View PDFchevron_right
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre
Ilaria Tarricone, Francesca Pastorelli
BMC …, 2006
View PDFchevron_right
Assessment of a Point-of-Care Metabolic Risk Screening Program in Outpatients Receiving Antipsychotic Agents
cherise rosen
Pharmacotherapy, 2009
View PDFchevron_right
Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality
David Henderson
The Journal of Clinical Psychiatry, 2005
View PDFchevron_right
The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial
Richard Josiassen
Journal of clinical psychopharmacology, 2018
View PDFchevron_right
Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study
Setareh Ranjbar
Schizophrenia Bulletin
View PDFchevron_right
Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database
Javier Rejas Gutiérrez
European Psychiatry, 2008
View PDFchevron_right
Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study
Jane Gagliardi
General Hospital Psychiatry, 2012
View PDFchevron_right
Improving Metabolic Syndrome Screening on Patients on Second Generation Antipsychotic Medication
Esther Kioko
Archives of Psychiatric Nursing, 2016
View PDFchevron_right
Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK
Sumera Bhatti
BMJ Open, 2015
View PDFchevron_right
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
Fernando Rico-Villademoros
Advances in Therapy
View PDFchevron_right
Metabolic Syndrome with Different Antipsychotics: A Multicentre Cross-Sectional Study
Mustafa Yildiz
View PDFchevron_right
Kidd, S* and Chopra, P* and Stone, J* and Jackson, T* and Gwee, K* and Maynard, S* and Ellis, IK and Judd, F*, ‘Monitoring of long-term cardia complications in patients receiving clozapine’, Australian Psychiatry, 21 (1) pp. 77-78. ISSN 1440-1665 (2012)
Isabelle Ellis
View PDFchevron_right
Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine
Paul Copeland
Journal of Psychiatric Practice, 2009
View PDFchevron_right
A narrative review of metabolic monitoring of adult prescribed second-generation antipsychotics for severe mental illness
Sahana Shetty
Clinical Epidemiology and Global Health, 2022
View PDFchevron_right